Market Overview

UPDATE: Bank of America Lowers Auxilium Pharmaceuticals PO to $25 Following 4Q12 Results

Related AUXL
Benzinga's Top Downgrades
Stifel Nicolaus Downgrades Auxilium Pharmaceuticals To Hold, Shares Drop

Bank of America published a report that reiterated Auxilium Pharmaceuticals (NASDAQ: AUXL) at Buy and trims price objective from $26 to $25.

Bank of America reported that, “We lowered our market growth assumptions for Testim based on recent Rx trends, and modestly increased our share estimates, which assume that AUXL's efforts to stabilize and grow share in 2013 are successful. These changes reduced our 2013E Testim sales to $252mn (from $257mn) and increased our 2014E sales to $302mn (from $293mn). We also lowered our Xiaflex sales estimates for 2013E to $71mn (from $85mn) and $104mn (from $119mn). Our new 2013E EPS is $0.15 (from $0.44) and our 2014E EPS is $0.98 (from $1.02).”

Auxilium Pharmaceuticals shares closed Tuesday at $17.06.

Latest Ratings for AUXL

Sep 2014Stifel NicolausDowngradesBuyHold
Sep 2014UBSDowngradesBuyNeutral
Sep 2014Leerink PartnersDowngradesOutperformMarket Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (AUXL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters